Tigecycline treatment of critically ill patients: The Latinuser experience

Current Clinical Pharmacology

Volumn 6, Issue 1, 2011, Pages 18-25

  Curcio, Daniel ^a,g   Vargas, Sandra Whittle ^b   Ubiergo, Sebastián Ugarte ^c   Varón, Fabio ^d   Suarez, José Rojas ^e   Chávez, Carlos Paz ^f   Curiale, Ariel ^g  

^a Instituto Sacre Cour   (Argentina)

^b Hospital de Urgencia Asistencia Pública Doctor Alejandro del Rio   (Chile)

^c HOSPITAL DEL SALVADOR   (Chile)

^d FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA   (Colombia)

^e Unidad de Cuidados Intensivos Gestión Salud   (Colombia)

^f Servicio de Geriatría del Hospital de la Fuerza Aérea del Perú   (Peru)

^g ClinicalREC   (Argentina)

Author keywords

Acinetobacter spp; Latin america; Multidrug resistant pathogens; Off label; Tigecycline; Ventilator associated pneumonia

Indexed keywords

TIGECYCLINE;

ACINETOBACTER; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM ISOLATION; CHILD; CRITICALLY ILL PATIENT; DRUG EFFICACY; ENTEROBACTERIACEAE; FEMALE; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INTERNET; MALE; MIDDLE AGED; MINOCYCLINE; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; PNEUMONIA, VENTILATOR-ASSOCIATED; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953057625     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488411794941304     Document Type: Article

References (35)

1. Giske CG, Monnet DL, Cars O, Carmeli Y. On behalf of ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52: 813-21.
2. Meyer E, Schwab F, Gastmeier P, Rueden H, Daschner FD. Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units (SARI): a summary of the data from 2001 through 2004. Infection 2006; 34: 303-9.
3. TEST progam [homepage on the Internet]. Available from: http://www.testsurveillance.com (last access January 7, 2009).
4. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. Colombian nosocomial resistance study group. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 2007; 51(4): 1553-5.
5. Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC. First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. Antimicrob Agents Chemother 2009; 53(1): 333-4.
6. Pasteran FG, Otaegui L, Guerriero L, et al. Klebsiella pneumoniae Carbapenemase-2, Buenos Aires, Argentina. Emerg Infect Dis 2008; 14(7): 1178-80.
7. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56(3): 470-80.
8. Blot S, De Waele J. Critical issues in the clinical management of complicated intraabdominal infections. Drugs 2005; 65: 1611-20.
9. Food and Drug Administration [homepage on the Internet]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/ (last access June 20, 2009).
10. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68: 140-51.
11. Curcio D, Fernández F, Duret F. Initial use of tigecycline in Argentina. Rev Chilena Infectol 2007; 24(6): 497-9.
12. Curcio D, Fernández F, Cané A, Barcelona L, Stamboulian D. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis 2008; 12: 198-201.
13. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40.
14. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamaseproducing Enterobacteriaceae: variability by site of infection. Arch Intern Med 2005; 165: 175-80.
15. Krieg NR, Holt JG. Bergeýs manual of systematic bacteriology, Baltimore, MD, USA: Williams & Wilkins 1984; vol. 1.
16. Clinical and Laboratory Standard Institute, Wayne, PA. CLSI document. Clinical and laboratory standard methods. Performance standards for antimicrobial susceptibility testing: seventeenth informational supplement; 2007; p. M100-S17.
17. Røder BL, Nielsen SL, Magnussen P, et al. Antibiotic usage in an intensive care unit in a Danish university hospital. J Antimicrob Chemother 1993; 32: 633-42.
18. Rintala E, Kairisto V, Eerola E, et al. Antimicrobial therapy of septicemic patients in intensive care units before and after blood culture reporting. Scand J Infect Dis 1991; 23: 341-6.
19. Raineri E, Pan A, Mondello P, et al. Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. Am J Infect Control 2008; 36: 283-90.
20. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006; 185: 544-8.
21. Biancofiore G, Tascini C, Bisà M, et al. Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant acinetobacter baumannii multifocal infection. A case report. Minerva Anestesiol 2007; 73: 181-5.
22. Piazza O, Iasiello A, PapaIanni C, et al. Incidence of antimicrobialresistant ventilator associated pneumonia: an eighteen-month survey. Panminerva Med 2005; 47: 265-7.
23. Bantar C, Famiglietti A, Radice M, Quinteros M. Antimicrobial Committee; SIR Participants Group. A 7-year national survey on bacterial resistance in bronchoalveolar lavage from patients hospitalized in Argentina. Diagn Microbiol Infect Dis 2008; 60(1): 65-9.
24. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-25.
25. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007; 27(7): 980-7.
26. Curcio D, Fernández F, Vergara J, Vazquez W, Luna CM. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009; 21: 58-62.
27. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
28. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-85.
29. Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008; 29: 160-9.
30. Tellado JM, Sen SS, Caloto MT, Kumar RN, Nocea G. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain. Scand J Infect Dis 2007; 39: 947-55.
31. Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with communityacquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23: 682-7.
32. Vogelaers D, De Bels D, Forêt F, et al. ANTHICUS Study Investigators. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients. Int J Antimicrob Agents 2010; 35: 375-81.
33. Curcio D, Alí A, Duarte A, et al. Prescription of antibiotics in intensive care units in Latin America: an observational study. J Chemother 2009; 21: 41-8.
34. Cuthbertson B. H, Thompson M, Sherry A, Wright M.M, Bellingan G.J. Intensive Care Society. Antibiotic-treated infections in intensive care patients in the UK. Anaesthesia 2004; 59: 885-90.
35. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Sep 2010, date last accessed).